“With multiple clinical trials ongoing, our focus is on execution to support several clinical readouts over the next three years that have the potential to unlock tremendous value of LB-102 in both psychosis and mood disorder indications,” said Heather Turner, CEO of LB Pharmaceuticals (LBRX). “We remain on track for topline data from NOVA-2 in schizophrenia in the second half of 2027, from ILLUMINATE-1 in bipolar depression in the first quarter of 2028 and in adjunctive MDD in the first half of 2029. Our recent successful financing supports the expansion of our pipeline and positions us to advance our strategy of building a fully integrated neuropsychiatric company.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals initiated with a Buy at H.C. Wainwright
- LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know
- Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy
- LB Pharmaceuticals initiated with a Buy at Craig-Hallum
- LB Pharmaceuticals files to sell 4.78M shares of common stock for holders